Nestlé Granted Patent for Green Coffee Insulin Treatment Composition
Summary
USPTO granted Patent US12599643B2 to Societe des Produits Nestle S.A. for green coffee-based compositions comprising hydrolysed chlorogenic acid for improving insulin profile. The patent covers compositions for treating or preventing disorders linked to increased plasma postprandial insulin, including esterase treated decaffeinated green coffee extract with 40-200 mg daily dosage. The patent contains 16 claims and was filed March 27, 2020.
What changed
USPTO granted Patent US12599643B2 to Societe des Produits Nestle S.A. covering green coffee-based compositions with hydrolysed chlorogenic acid for improving insulin profile and treating disorders linked to increased postprandial insulin. The patent includes 16 claims and covers compositions with 40-200 mg esterase treated decaffeinated green coffee extract administered daily.
This patent grant provides Nestlé with exclusive rights to the green coffee composition technology for insulin-related applications. Competitors developing similar products for insulin profile improvement should review this patent to assess potential infringement risks. No compliance obligations are imposed on other parties by this grant.
What to do next
- Monitor for updates
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Use of green coffee based compositions for improving insulin profile
Grant US12599643B2 Kind: B2 Apr 14, 2026
Assignee
Societe des Produits Nestle S.A.
Inventors
Lucas Actis Goretta, Jacklyn Ruilin Chen, Rachid Bel-Rhlid, Robin Willows, Marine Kraus, Christian Chabert
Abstract
The present invention relates to a green coffee-based composition comprising hydrolysed chlorogenic acid for use in the treatment or prevention of a disorder linked to an increase in plasma postprandial insulin in a subject. The invention relates also to the non-therapeutic use of a composition comprising an esterase treated decaffeinated green coffee extract with an amount of 40-200 mg administered to a subject per day to decrease plasma postprandial insulin concentration. A further aspect of the invention is a process for forming green coffee based compositions.
CPC Classifications
A61K 36/74 A61K 31/192 A23F 3/166 A23F 3/18 A23F 3/22 A61P 3/10
Filing Date
2020-03-27
Application No.
17442213
Claims
16
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.